Panel Discussion | Navigating Payers Perspectives & Moving Towards Surrogate Endpoints to Demonstrate Reimbursement for CKD Patient Populations
Time: 1:00 pm
day: Day 2 Track 3 PM
Details:
- How important is having hard outcomes data vs a surrogate measure of CKD progression or improvement?
- What will it take to pivot away from hard endpoints to demonstrate convincing evidence of improvements in renal function?
- What are the clinical evidence requirements from payers and insurers to demonstrate reimbursement and offer effective therapies to CKD patients sooner?
